Therapeutics News and Research

RSS
Provectus Pharmaceuticals commences compassionate use program of PV-10 for cancer

Provectus Pharmaceuticals commences compassionate use program of PV-10 for cancer

Presentation on L-DOS47 drug formulation and development at Pharmaceutical Industry Conference

Presentation on L-DOS47 drug formulation and development at Pharmaceutical Industry Conference

Antisense Therapeutics completes repeat-dosing toxicology studies for ATL1103

Antisense Therapeutics completes repeat-dosing toxicology studies for ATL1103

2010 TIPPS certification for Prime Therapeutics

2010 TIPPS certification for Prime Therapeutics

Cequent Pharmaceuticals to provide details of its clinical program at BIOCOM conference

Cequent Pharmaceuticals to provide details of its clinical program at BIOCOM conference

Case Western Reserve University receives a $20.5M gift to support medical education and research programs

Case Western Reserve University receives a $20.5M gift to support medical education and research programs

Positive results from BioMimetic Therapeutics' Phase III trial comparing Augment Bone Graft to autograft

Positive results from BioMimetic Therapeutics' Phase III trial comparing Augment Bone Graft to autograft

Onyx Pharmaceuticals signs definitive agreement to acquire Proteolix

Onyx Pharmaceuticals signs definitive agreement to acquire Proteolix

SAFC Pharma expands contract manufacturing services

SAFC Pharma expands contract manufacturing services

Amsterdam Molecular Therapeutics' AMT-080 granted EMEA Orphan Drug Designation

Amsterdam Molecular Therapeutics' AMT-080 granted EMEA Orphan Drug Designation

ImaginAb and BZL Biologics conclude sublicense agreement for antibody technology

ImaginAb and BZL Biologics conclude sublicense agreement for antibody technology

CED to host popular STREAK program

CED to host popular STREAK program

Nektar Therapeutics presents the results from Phase 2 clinical trial of oral NKTR-118

Nektar Therapeutics presents the results from Phase 2 clinical trial of oral NKTR-118

Heptares Therapeutics to apply its StaR technology to generate novel drug leads against GPCR target

Heptares Therapeutics to apply its StaR technology to generate novel drug leads against GPCR target

Pieris reports its progress in the development of PRS-050

Pieris reports its progress in the development of PRS-050

Crescendo Biologics raises funds to advance the development of its fragment antibody technology platforms

Crescendo Biologics raises funds to advance the development of its fragment antibody technology platforms

Researchers find SNARE-like protein system to help bacteria avoid cell destruction

Researchers find SNARE-like protein system to help bacteria avoid cell destruction

RXi Pharmaceuticals presents new preclinical data from its advanced RNAi therapeutic platform

RXi Pharmaceuticals presents new preclinical data from its advanced RNAi therapeutic platform

New York Governor participates in roundtable discussion on stem cell research

New York Governor participates in roundtable discussion on stem cell research

Hospira and Celltrion agree to develop and market eight biogeneric products

Hospira and Celltrion agree to develop and market eight biogeneric products

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.